Alaskan SWF Invests in Series B on Anti-Cancer Biotech

The Alaska Permanent Fund Corporation (APFC) participated in a US$ 61 million Series B round to invest in Cambridge, Massachusetts-based Codiak BioSciences Inc., a company focused on the advanced research and clinical development of exosomes, which are tiny membrane sacs, or vesicles, that are released by both healthy and cancerous cells, for therapeutic and diagnostic purposes. [ Content protected for Sovereign Wealth Fund Institute Standard subscribers only. Please subscribe to view content. ]

Contact the writer or creator of this article or page.
Questions or comments: support(at)swfinstitute(dot)org
Follow on Twitter at @swfinstitute and @sovereignfunds
Learn, Attend and Network: Institutional Investor Events and Summits
Go Back: HOME: Sovereign Wealth Fund Institute
institutional investor investment mandates